Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 19/20 | 0.79 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.77 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.77 |
| ▸ | AGTR2 | P50052 | 8/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10046740 | 0.95 | AGTR1 (0.76) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL30602652 | 0.90 | AGTR1 (0.83) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL16691910 | 0.89 | AGTR1 (0.82) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL18387996 | 0.88 | AGTR1 (1.00) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL16482977 | 0.87 | AGTR1 (0.86) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| Valsartan SCHEMBL29518879 | 0.87 | AGTR1 (1.00) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| SCHEMBL20257282 | 0.87 | AGTR1 (0.86) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| Valsartan SCHEMBL678796 | 0.87 | AGTR1 (1.00) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| Valsartan SCHEMBL24722321 | 0.87 | AGTR1 (1.00) | AGTR1LTB4R2ABCB11GP6AGTR2 | |
| Valsartan SCHEMBL678231 | 0.87 | AGTR1 (1.00) | AGTR1LTB4R2ABCB11GP6AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220175667-A1 | Extracellular Matrices, Uses Thereof, and Methods of Making Extracellular Matrices | THE JOHNS HOPKINS UNIVERSITY | 2022-06-09 | — | — | US | disclosed |
| US-20210069375-A1 | Extracellular Matrices, Uses thereof, and Method for Making Extracellular Matrices | THE JOHNS HOPKINS UNIVERSITY | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210069375-A1 | Extracellular Matrices, Uses thereof, and Method for Making Extracellular Matrices | MMP1, MATR3, COL1A1 | AGTR1 3981/4885LTB4R2 553/4885ABCB11 1522/4885 |
| US-20220175667-A1 | Extracellular Matrices, Uses Thereof, and Methods of Making Extracellular Matrices | EPCAM, CD44, MATR3 | AGTR1 3754/4885LTB4R2 629/4885ABCB11 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.